Literature DB >> 402421

Immunologic reactivity of purified human urinary kallikrein (urokallikrein) with antiserum directed against human pancreas.

O ole-Moi Yoi, J Spragg, S P Halbert, K F Austen.   

Abstract

Donkey antiserum to normal human pancreas absorbed with lyophilized human plasma recognized human urokallikrein in concentrated crude urine or after an approximately 500-fold purification. The urokallikrein antigen was associated with kinin-generating and alpha-N-p-tosyl-L-arginine methyl ester (TAMe) cleaving activity on isoelectric focusing, with the isoelectric point being 3.8 to 4.4. Both kiningenerating and esterolytic activity were removed from the purified urokallikrein by an immunoadsorbent prepared by coupling the IgG fraction of the absorbed donkey antiserum to Sepharose 6B. The failure of anti-plasma kallikrein to react in immunodiffusion with purified urokallikrein indicates that urinary kallikrein is distinct from plasma kallikrein although antigenically related to glandular kallikreins.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 402421

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  4 in total

Review 1.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 2.  The kallikrein-kinin system in circulatory and metabolic homeostasis.

Authors:  R McConn; G L Haberland; J C Frölich
Journal:  World J Surg       Date:  1981-07       Impact factor: 3.352

3.  Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens.

Authors:  M Maier; K F Austen; J Spragg
Journal:  Proc Natl Acad Sci U S A       Date:  1983-07       Impact factor: 11.205

4.  Sequential cleavage of proinsulin by human pancreatic kallikrein and a human pancreatic kininase.

Authors:  O O Yoi; D C Seldin; J Spragg; G S Pinkus; K F Austen
Journal:  Proc Natl Acad Sci U S A       Date:  1979-08       Impact factor: 11.205

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.